Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Diffuse Large B-cell Lymphoma
- Sponsor
- Institut Claudius Regaud
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Levels of blood biomarkers to determine if it reflect the disease evolution of patient with DLBCL treated in first line.
- Status
- Completed
- Last Updated
- 4 months ago
Overview
Brief Summary
This trial is a translational, prospective, open-label, monocentric research.
The study will be conducted in a population of 60 patients with diffuse large B-cell lymphoma (DLBCL) for whom first-line treatment with R-CHOP is planned as part of their standard of care.
SIMILY program aims at identifying biomarkers and/or molecular signatures related to immuno-phenotypic and -genotypic characteristics of the tumor and immune microenvironment, at the time of diagnosis, during R-CHOP, and at 24 months or time of progression.
Each patient will be followed during 2 years.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP (treatment by R-CHOP should not have been initiated prior to inclusion in the study)
- •Age 18 to 80 years at the time of study entry
- •Archived initial diagnostic tumor specimen available
- •Life expectancy ≥ 3months
- •ECOG Performance status 0-2
- •FDG-avid disease (for PET monitoring)
- •Signed written informed consent
- •Patient able to participate and willing to give informed consent prior performance of any study-related procedures and to comply with the study protocol
- •Patient affiliated to a Social Health Insurance in France
Exclusion Criteria
- •Patient pregnant, or breast-feeding
- •Any condition contraindicated with tumor / blood sampling procedures required by the protocol
- •Central Nervous System (CNS) involvement
- •Known history of positive test for Hepatitis B virus or Hepatitis C virus or Immunodeficiency Virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
- •Any current severe or uncontrolled disease, including, but not limited to ongoing or active infection and auto immune disorders
- •Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure
- •Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)
- •Current participation in any other therapeutic clinical study
Outcomes
Primary Outcomes
Levels of blood biomarkers to determine if it reflect the disease evolution of patient with DLBCL treated in first line.
Time Frame: 24 months for each patient
Blood biomarkers will be identified by ScRNA sequencing.
Levels of ctDNA to determine if it reflect the disease evolution of patient with DLBCL treated in first line.
Time Frame: 24 months for each patient
Levels of tumor tissue biomarkers to determine if it reflect the disease evolution of patient with DLBCL treated in first line.
Time Frame: 24 months for each patient
Tumor tissue biomarkers will be identified by ScRNA sequencing and targeted NGS.
Secondary Outcomes
- Levels of tumor tissue biomarkers compared to clinical data in the prediction of treatment response.(24 months for each patient)
- Levels of blood biomarkers compared to clinical data in the prediction of treatment response.(24 months for each patient)
- Levels of ctDNA compared to conventional PET imaging (at the standard time points) in the prediction of treatment response.(24 months for each patient)